Compare IDEXX Laboratories, Inc. (IDXX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Synchrony Financial — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Synchrony Financial pays a 1.84% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Synchrony Financial for 29 Days on average.
| IDXX | SYF | |
|---|---|---|
Market Cap | $40.43B | $23.99B |
Volume | 692,164 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $766.68 | $88.47 |
52-Week Low | $504.70 | $63.78 |
Typical Hold Time | 46 Days | 29 Days |
Enterprise Value | $41.32B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Synchrony Financial (SYF) trades at $73.72, up 2.49% with strong technical support at $72 and resistance at $75. The stock shows compelling value with a P/E of 7.56 and ROE of 22.23%, supported by three consecutive earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing expansion.
SYF presents an attractive investment case with undervalued fundamentals and positive analyst sentiment, though technical indicators show mixed signals with RSI suggesting potential overbought conditions. Key risks include consumer credit quality concerns and competitive pressures in the financial services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
